ImpediMed Limited (IPD.AX)
| Previous close | 0.0940 |
| Open | 0.0960 |
| Bid | 0.0890 x 53590500 |
| Ask | 0.0940 x 50748300 |
| Day's range | 0.0890 - 0.0960 |
| 52-week range | 0.0890 - 0.2050 |
| Volume | |
| Avg. volume | 1,410,200 |
| Market cap | 158.231M |
| Beta (5Y monthly) | 3.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0130 |
| Earnings date | 22 Aug 2022 - 28 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.32 |
- PR Newswire
New Bone Data Showing Strong Correlation between ImpediMed's SOZO and DXA in Cancer Patients Presented at 39th Annual Miami Breast Cancer Conference
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce a poster showing strong correlation between ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was presented at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA.
- Simply Wall St.
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- PR Newswire
New Data Evaluating ImpediMed's SOZO® Digital Health Platform to Assess Bone in Cancer Patients to be Presented at 39th Annual Miami Breast Cancer Conference
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce an abstract comparing concurrent measures using ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was accepted for poster presentation at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA
